InMed Pharmaceuticals Inc.
INM Nasdaq
SEC CIK 1728328
Follow InMed Pharmaceuticals
Weekly email: filings, results, news
Net income
−$5.8M
−226.5% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$3M
−40.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | - | −$12.6M |
| FY25 | $4.9M | −$8.2M |
| FY24 | $4.6M | −$7.7M |
| FY23 | $4.1M | −$7.9M |
| FY22 | $1.4M | −$18.6M |
| FY21 | $1.9M | −$10.2M |
| FY20 | - | −$8.9M |
| FY19 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | - | - | - |
| FY25 | 34.5% | - | −165.1% |
| FY24 | 23.9% | - | −166.9% |
| FY23 | 33.9% | −192.2% | −192.2% |
| FY22 | 39.8% | −1361.9% | −1361.9% |
| FY21 | - | −535.9% | −535.9% |
| FY20 | - | - | - |
| FY19 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | - |
| FY25 | −$8.1M |
| FY24 | −$7M |
| FY23 | −$7.4M |
| FY22 | −$15.6M |
| FY21 | −$9.8M |
| FY20 | −$7.4M |
| FY19 | - |
- InMed Pharmaceuticals
- Healthcare median
Show the numbers
| Year | InMed Pharmaceuticals | Healthcare median |
|---|---|---|
| FY26 | - | −19.9% |
| FY25 | −165.1% | −40.6% |
| FY24 | −166.9% | −60.7% |
| FY23 | −192.2% | −97.1% |
| FY22 | −1361.9% | −128.5% |
| FY21 | −535.9% | −129.2% |
| FY20 | - | −136.5% |
| FY19 | - | −133.7% |
News
No stories filed under InMed Pharmaceuticals yet - coverage appears here as the news feed clusters it.